Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBP-301 and Chemoradiation in Locally Advanced Esophageal and Gastroesophageal Cancer
NCT04391049Phase 1Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suratadenoturev in esophageal cancer and gastroesophageal junction cancer, sponsored by NRG Oncology. Primary endpoint: Dose-Limiting Toxicities at 10 weeks. Started Dec 2021; status: active, not recruiting.
02
Drugs
suratadenoturev
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04391049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391049.